Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
NATURAL CAPS ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NATURAL CAPS Mar-23 |
ADCOCK INGRAM Jun-14 |
NATURAL CAPS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 679 | 321 | - | |
Low | Rs | 374 | 232 | - | |
Sales per share (Unadj.) | Rs | 184.4 | 95.5 | - | |
Earnings per share (Unadj.) | Rs | 19.7 | -24.1 | - | |
Cash flow per share (Unadj.) | Rs | 27.4 | -20.0 | - | |
Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
Avg Dividend yield | % | 0.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 131.8 | 75.0 | - | |
Shares outstanding (eoy) | m | 9.35 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.9 | 2.9 | 98.7% | |
Avg P/E ratio | x | 26.7 | -11.5 | -232.4% | |
P/CF ratio (eoy) | x | 19.2 | -13.9 | -138.5% | |
Price / Book Value ratio | x | 4.0 | 3.7 | 108.4% | |
Dividend payout | % | 5.1 | 0 | - | |
Avg Mkt Cap | Rs m | 4,922 | 46,656 | 10.6% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 95 | 2,928 | 3.2% | |
Avg. sales/employee | Rs Th | 0 | 3,756.2 | - | |
Avg. wages/employee | Rs Th | 0 | 682.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -946.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,724 | 16,125 | 10.7% | |
Other income | Rs m | 16 | 113 | 14.3% | |
Total revenues | Rs m | 1,740 | 16,238 | 10.7% | |
Gross profit | Rs m | 343 | -2,794 | -12.3% | |
Depreciation | Rs m | 72 | 696 | 10.4% | |
Interest | Rs m | 37 | 437 | 8.5% | |
Profit before tax | Rs m | 250 | -3,814 | -6.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 65 | 238 | 27.5% | |
Profit after tax | Rs m | 184 | -4,063 | -4.5% | |
Gross profit margin | % | 19.9 | -17.3 | -114.9% | |
Effective tax rate | % | 26.2 | -6.2 | -419.2% | |
Net profit margin | % | 10.7 | -25.2 | -42.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,015 | 11,810 | 8.6% | |
Current liabilities | Rs m | 669 | 6,645 | 10.1% | |
Net working cap to sales | % | 20.1 | 32.0 | 62.6% | |
Current ratio | x | 1.5 | 1.8 | 85.3% | |
Inventory Days | Days | 6 | 111 | 5.3% | |
Debtors Days | Days | 1,104 | 124 | 890.6% | |
Net fixed assets | Rs m | 1,873 | 6,884 | 27.2% | |
Share capital | Rs m | 93 | 75 | 123.9% | |
Net worth | Rs m | 1,232 | 12,657 | 9.7% | |
Long term debt | Rs m | 704 | 4,448 | 15.8% | |
Total assets | Rs m | 2,888 | 23,909 | 12.1% | |
Interest coverage | x | 7.7 | -7.7 | -99.6% | |
Debt to equity ratio | x | 0.6 | 0.4 | 162.5% | |
Sales to assets ratio | x | 0.6 | 0.7 | 88.5% | |
Return on assets | % | 7.7 | -15.2 | -50.6% | |
Return on equity | % | 15.0 | -32.1 | -46.6% | |
Return on capital | % | 14.8 | -19.8 | -74.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 172 | 1,376 | 12.5% | |
From Investments | Rs m | -1,046 | -423 | 247.6% | |
From Financial Activity | Rs m | 875 | 4,037 | 21.7% | |
Net Cashflow | Rs m | 1 | 4,990 | 0.0% |
Compare NATURAL CAPS With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare NATURAL CAPS With: BAFNA PHARMA VISTA PHARMA SHAMROCK IND AAYUSH FOOD & HERBS COLINZ LABOR
Asian stocks inched higher on Tuesday as investors awaited a slew of economic data, corporate earnings and the U.S. Federal Reserve's policy meeting.